{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=53",
    "query": {
      "intervention": "Control Study Product",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 4237,
    "total_pages": 424,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T18:43:19.822Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00288704",
      "title": "Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Cold Autoinflammatory Syndrome (FCAS)",
        "Familial Cold Urticaria",
        "Muckle-Wells Syndrome (MWS)",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "rilonacept 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2005-12",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-12-06",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288704"
    },
    {
      "nct_id": "NCT01117038",
      "title": "Drug Interaction Study of Avanafil and Enalapril or Amlodipine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "avanafil and enalapril",
          "type": "DRUG"
        },
        {
          "name": "avanafil and amlodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "40 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2010-04",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2011-08-10",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117038"
    },
    {
      "nct_id": "NCT05026658",
      "title": "Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Digital Acuity Product"
      ],
      "interventions": [
        {
          "name": "Visibly Digital Acuity Product",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Visibly",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "22 Years to 40 Years"
      },
      "enrollment_count": 358,
      "start_date": "2021-07-22",
      "completion_date": "2021-10-04",
      "has_results": false,
      "last_update_posted_date": "2024-11-04",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 3,
      "location_summary": "Andover, Massachusetts • Shelby, North Carolina • Memphis, Tennessee",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05026658"
    },
    {
      "nct_id": "NCT00179335",
      "title": "Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Blood drawing to determine drug levels",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2003-08",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179335"
    },
    {
      "nct_id": "NCT05304767",
      "title": "An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Xanomeline and Trospium Chloride Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 290,
      "start_date": "2022-03-07",
      "completion_date": "2026-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05304767"
    },
    {
      "nct_id": "NCT00241904",
      "title": "Reducing Total Cardiovascular Risk in an Urban Community",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Heart Diseases",
        "Coronary Disease",
        "Diabetes Mellitus",
        "Atherosclerosis",
        "Cerebral Arteriosclerosis",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Lifestyle Changes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Antiplatelet Agents",
          "type": "DRUG"
        },
        {
          "name": "Beta Blocker",
          "type": "DRUG"
        },
        {
          "name": "ACE Inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 525,
      "start_date": "2006-05",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241904"
    },
    {
      "nct_id": "NCT01544348",
      "title": "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Asthma",
        "Atopic Dermatitis",
        "Allergic Rhinitis",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 5 mg Subcutaneous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 15 mg Subcutaneous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 60 mg Subcutaneous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 150 mg Subcutaneous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 300 mg Subcutaneous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4212 300 mg Intravenous",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 295,
      "start_date": "2012-01",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-30",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 7,
      "location_summary": "Cypress, California • Glendale, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544348"
    },
    {
      "nct_id": "NCT07229911",
      "title": "A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "TAK-781",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 134,
      "start_date": "2026-01-07",
      "completion_date": "2028-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07229911"
    },
    {
      "nct_id": "NCT00325728",
      "title": "Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Insomnia"
      ],
      "interventions": [
        {
          "name": "Ramelteon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2006-03-21",
      "completion_date": "2007-08-20",
      "has_results": false,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 72,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325728"
    },
    {
      "nct_id": "NCT00262067",
      "title": "A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1237,
      "start_date": "2005-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2013-12-13",
      "last_synced_at": "2026-10-29T18:43:19.822Z",
      "location_count": 5,
      "location_summary": "Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262067"
    }
  ]
}